WO1998002558A3 - Chimeric receptors for jak-stat signal transduction - Google Patents

Chimeric receptors for jak-stat signal transduction Download PDF

Info

Publication number
WO1998002558A3
WO1998002558A3 PCT/US1997/012456 US9712456W WO9802558A3 WO 1998002558 A3 WO1998002558 A3 WO 1998002558A3 US 9712456 W US9712456 W US 9712456W WO 9802558 A3 WO9802558 A3 WO 9802558A3
Authority
WO
WIPO (PCT)
Prior art keywords
cytokine
epor
cells
intracellular domain
jak
Prior art date
Application number
PCT/US1997/012456
Other languages
French (fr)
Other versions
WO1998002558A2 (en
Inventor
Sidney Pestka
Serguei V Kotenko
Original Assignee
Univ New Jersey Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New Jersey Med filed Critical Univ New Jersey Med
Priority to AU36688/97A priority Critical patent/AU3668897A/en
Publication of WO1998002558A2 publication Critical patent/WO1998002558A2/en
Publication of WO1998002558A3 publication Critical patent/WO1998002558A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The invention provides a chimeric receptor for cellular activation comprising an extracellular domain capable of binding to a cognate molecule, and a cytokine intracellular domain capable of interacting with a Jak-Stat protein, thereby participating in signal transduction, with the proviso that the cytokine intracellular domain is not naturally associated with the extracellular domain. The present invention harnesses cytokine and growth factor receptor cellular activation pathways for responses to different receptor ligands, thus enabling reconstitution of cellular activation to a ligand, such as a cytokine or growth factor, where some deficiency prevents activation by the native pathway; targeting of effector cells to tumors, virally infected cells, or autoimmune cells; and creating new cytokine or growth factor sensitivities in responder cells, e.g., to develop an assay system in which cells not normally responsive to a given cytokine are rendered responsive. In specific embodiments, the cytokine intracellular domain interacts with a Jak protein selected from the group consisting of Jak1, Jak2, Jak3, and Tyk2. In another embodiment, preferably the cytokine intracellular domain interacts with a Stat protein selected from the group consisting of Stat1α, Stat1β, Stat2, Stat3, Stat4, Stat5 and Stat6. In specific examples, various functional chimeric constructs, including ηR2/ηR1, ηR2/αR1, ηR2/αR2, ηR2/CRF, ηR2/ηC, IL-10R/ηR1, EpoR/ηR1, EpoR/ηR2, ηR1/EpoR, ηR2/EpoR, H1/ηR1, and L1/ηR2, were prepared.
PCT/US1997/012456 1996-07-17 1997-07-17 Chimeric receptors for jak-stat signal transduction WO1998002558A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU36688/97A AU3668897A (en) 1996-07-17 1997-07-17 Chimeric receptors for jak-stat signal transduction

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68374496A 1996-07-17 1996-07-17
US08/683,744 1996-07-17

Publications (2)

Publication Number Publication Date
WO1998002558A2 WO1998002558A2 (en) 1998-01-22
WO1998002558A3 true WO1998002558A3 (en) 1998-05-07

Family

ID=24745281

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/012456 WO1998002558A2 (en) 1996-07-17 1997-07-17 Chimeric receptors for jak-stat signal transduction

Country Status (2)

Country Link
AU (1) AU3668897A (en)
WO (1) WO1998002558A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6472179B2 (en) * 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
CN110191955B (en) * 2016-12-13 2024-05-31 西雅图儿童医院（Dba西雅图儿童研究所） Method for exogenous drug activation of chemical-induced signaling complexes expressed in engineered cells in vitro and in vivo
MX2020009051A (en) * 2018-03-02 2020-12-03 Allogene Therapeutics Inc Inducible chimeric cytokine receptors.
SG11202007874XA (en) 2018-04-27 2020-09-29 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Rapamycin resistant cells
MX2021010444A (en) 2019-03-01 2021-09-21 Allogene Therapeutics Inc Chimeric cytokine receptors bearing a pd-1 ectodomain.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011303A1 (en) * 1993-10-20 1995-04-27 Regeneron Pharmaceuticals, Inc. Cntf family antagonists
WO1996004389A1 (en) * 1994-08-04 1996-02-15 Regeneron Pharmaceuticals, Inc. Rtk/cytokine receptor chimeras
EP0704532A2 (en) * 1994-06-10 1996-04-03 United States Surgical Corporation Recombinant chimeric proteins and methods of use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011303A1 (en) * 1993-10-20 1995-04-27 Regeneron Pharmaceuticals, Inc. Cntf family antagonists
EP0704532A2 (en) * 1994-06-10 1996-04-03 United States Surgical Corporation Recombinant chimeric proteins and methods of use thereof
WO1996004389A1 (en) * 1994-08-04 1996-02-15 Regeneron Pharmaceuticals, Inc. Rtk/cytokine receptor chimeras

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GAFFEN SL ET AL: "Signaling through the interleukin 2 receptor beta chain activates a STAT-5-like DNA-binding activity.", PROC NATL ACAD SCI U S A, AUG 1 1995, 92 (16) P7192-6, UNITED STATES, XP002042093 *
STAHL N ET AL: "Choice of STATs and other substrates specified by modular tyrosine-based motifs in cytokine receptors.", SCIENCE, MAR 3 1995, 267 (5202) P1349-53, UNITED STATES, XP002042092 *
VIE H ET AL: "Human fusion proteins between interleukin 2 and IgM heavy chain are cytotoxic for cells expressing the interleukin 2 receptor.", PROC NATL ACAD SCI U S A, DEC 1 1992, 89 (23) P11337-41, UNITED STATES, XP002045847 *

Also Published As

Publication number Publication date
WO1998002558A2 (en) 1998-01-22
AU3668897A (en) 1998-02-09

Similar Documents

Publication Publication Date Title
Kwon et al. A newly identified member of the tumor necrosis factor receptor superfamily with a wide tissue distribution and involvement in lymphocyte activation
Lacronique et al. Transforming properties of chimeric TEL-JAK proteins in Ba/F3 cells
Aman et al. cDNA cloning and characterization of the human interleukin 13 receptor α chain
Rui et al. Prolactin receptor triggering. Evidence for rapid tyrosine kinase activation.
MALABARBA et al. Interleukin-13 is a potent activator of JAK3 and STAT6 in cells expressing interleukin-2 receptor-γ and interleukin-4 receptor-α
Rowlinson et al. Activation of chimeric and full-length growth hormone receptors by growth hormone receptor monoclonal antibodies: a specific conformational change may be required for full-length receptor signaling
CN101605810B (en) Chimeric human sweet-umami and umami-sweet taste receptors
ES2133271T3 (en) RECEIVERS FOR FIBROBLAST GROWTH FACTORS.
WO1998030693A3 (en) Tumor necrosis factor receptor 5
EP0871726A4 (en) Multispecific chimeric receptors
Ishizaka-Ikeda et al. Signal transduction mediated by growth hormone receptor and its chimeric molecules with the granulocyte colony-stimulating factor receptor.
LEFKOWITZ et al. Molecular and regulatory properties of adrenergic receptors
WO2000025725A3 (en) Functional antagonists of hedgehog activity
VANLINGEN et al. Ca2+ and calmodulin differentially modulate myo-inositol 1, 4, 5-trisphosphate (IP3)-binding to the recombinant ligand-binding domains of the various IP3 receptor isoforms
WO1998002558A3 (en) Chimeric receptors for jak-stat signal transduction
IL138593A (en) Glial factor receptor ??3 (gfr??3) polypeptide, nucleic acid encoding the same, process for preparation thereof, vectors, host cells, antibodies, chimeric molecules and use of such gfr??3
Witthuhn et al. Differential substrate recognition capabilities of Janus family protein tyrosine kinases within the interleukin 2 receptor (I12R) system: Jak3 as a potential molecular target for treatment of leukemias with a hyperactive Jak-Stat signaling machinery
Kondo et al. Expression and functional characterization of artificial mutants of interleukin-2 receptor
Cole et al. Disulfide bond structure and N-glycosylation sites of the extracellular domain of the human interleukin-6 receptor
DE69841176D1 (en) Rtd receptor
Pacifici et al. Hybrid tyrosine kinase/cytokine receptors transmit mitogenic signals in response to ligand.
Hill et al. Differentiation induced by the c-Mpl cytokine receptor is blocked by mutant Shc adaptor protein
Choi Cloning and characterization of a naturally occurring soluble form of TGF-β type I receptor
Ferrag et al. Convergence of signaling transduced by prolactin (PRL)/cytokine chimeric receptors on PRL-responsive gene transcription.
Heguy et al. A chimeric type II/type I interleukin-1 receptor can mediate interleukin-1 induction of gene expression in T cells

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AU BA BB BG BR CA CN CU CZ EE GE GH HU IL IS JP KP KR LC LK LR LT LV MG MK MN MX NO NZ PL RO SG SI SK SL TR TT UA UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998506284

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase